For 34 HCC samples with higher PTPN13 expression, there were 20 (58.82%) HCC samples with stage 1–2 disease, but among 73 HCC samples with increased IGF2PB1 expression, there are only 28 (38.36%) HCC samples with stage 1–2 disease (Fig. 8D). This evidence concerns the gene PTPN13 and hepatocellular carcinoma.